ArticleScientific reports2026
Plasma lipid remodeling during the early recovery phase after myocardial infarction.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myocardial infarction (MI) induces extensive disturbances in lipid homeostasis; however, most lipidomic studies have focused on the acute hours-to-days phase or the chronic months-to-years period. To the best of our knowledge, this is the first study to characterize plasma lipidomic patterns specifically during the early recovery window (3–6 weeks post-MI), a clinically stable yet biochemically active stage of healing. We compared plasma lipid profiles—including phospholipids, sphingomyelins (SMs), and ceramides (Cers)—in acute MI patients, early-recovery patients, and healthy controls. LC-MS lipidomics revealed marked depletion of polyunsaturated phosphatidylcholines (PCs) and plasmalogens during MI. During recovery, PC-derived plasmalogens showed partial restoration, whereas PE-derived plasmalogens remained suppressed. Lysophospholipids were elevated acutely but normalized by 3–6 weeks, coinciding with improvements in systemic inflammatory markers. Saturated and monounsaturated PCs increased during recovery. Distinct alterations were also observed in sphingolipids. Ceramide species remained elevated during early recovery, while SM levels partially declined. Pathway analysis indicated that MI most strongly disrupted glycerophospholipid metabolism, arachidonic acid metabolism, and sphingolipid-related pathways, whereas the recovery group showed only partial metabolic normalization. By focusing on an underexplored transitional window, this study provides descriptive insight into post-infarction lipid remodeling and suggests that plasma lipidomics may capture both acute injury and early recovery-related metabolic states under contemporary clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.